Med.Chem.Cool

FDA Grants TransTech Pharma Inc. Fast Track Designation for TTP488 for the Treatment of Alzheimer’s Disease

 BusinessWire · Mar. 18, 2013 | Last Updated: Mar. 18, 2013 6:00 PM ET

TransTech Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for TTP488, a new small-molecule chemical compound being developed for the treatment of Alzheimer’s disease. TTP488 prevents the interaction of amyloid beta (Aβ), a material found in the cells of Alzheimer’s patients, and a member of the immunoglobulin supergene family of molecules known as the Receptor for Advanced Glycation Endproducts (RAGE). TTP488 is the first drug related to RAGE, a relatively new biological target in Alzheimer’s disease research, with demonstrated success in multiple clinical trials. TransTech Pharma discovered, developed and owns the rights to this drug candidate.

The FDA’s Fast Track designation is granted to development products intended for the treatment…

View original post 314 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s